MX394102B - Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal. - Google Patents

Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal.

Info

Publication number
MX394102B
MX394102B MX2018013438A MX2018013438A MX394102B MX 394102 B MX394102 B MX 394102B MX 2018013438 A MX2018013438 A MX 2018013438A MX 2018013438 A MX2018013438 A MX 2018013438A MX 394102 B MX394102 B MX 394102B
Authority
MX
Mexico
Prior art keywords
colorectal cancer
pharmaceutical compositions
effective treatment
kras4b
compound
Prior art date
Application number
MX2018013438A
Other languages
English (en)
Other versions
MX2018013438A (es
Inventor
Mejia Miguel Ángel Vargas
Díaz Paola Briseño
NOVA Predro CRUZ
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N filed Critical Centro De Investig Y De Estudios Avanzados Del I P N
Priority to MX2018013438A priority Critical patent/MX394102B/es
Priority to PCT/IB2019/059380 priority patent/WO2020089842A1/en
Publication of MX2018013438A publication Critical patent/MX2018013438A/es
Publication of MX394102B publication Critical patent/MX394102B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe composiciones farmacéuticas que comprenden el compuesto de fórmula (ver Fórmula) (compuesto C19) que inhibe específicamente la GTPasa KRAS4b mutada, por lo que resultan útiles para el tratamiento efectivo del cáncer colorectal. El compuesto C19 funciona como un estabilizador del complejo KRAS4b-PDEd, disminuyendo la proliferación de células cancerosas en cáncer colorectal, y aumentando la apoptosis a través de la disminución de la activación de la señalización oncogénica de KRAS4b.
MX2018013438A 2018-11-01 2018-11-01 Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal. MX394102B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2018013438A MX394102B (es) 2018-11-01 2018-11-01 Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal.
PCT/IB2019/059380 WO2020089842A1 (en) 2018-11-01 2019-11-01 Pharmaceutical compositions for the effective treatment of colorectal cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018013438A MX394102B (es) 2018-11-01 2018-11-01 Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal.

Publications (2)

Publication Number Publication Date
MX2018013438A MX2018013438A (es) 2022-07-20
MX394102B true MX394102B (es) 2025-03-21

Family

ID=70463876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013438A MX394102B (es) 2018-11-01 2018-11-01 Composiciones farmaceuticas para el tratamiento efectivo de cancer colorectal.

Country Status (2)

Country Link
MX (1) MX394102B (es)
WO (1) WO2020089842A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c

Also Published As

Publication number Publication date
MX2018013438A (es) 2022-07-20
WO2020089842A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CY1125356T1 (el) Παραγωγα ν-πυριδινυλιου ως αναστολεις της οδου σηματοδοτησης wnt
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
CY1123592T1 (el) Αναστολεας κινασης aurora a
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
GEP20217281B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
SA523440283B1 (ar) مركبات مضادة للأورام
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
EA201591509A1 (ru) Ингибиторы cdc7
MX374946B (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2018008895A (es) Compuestos de 2-oxindol.
MX2019002430A (es) Agente antitumoral, mejorador del efecto antitumoral, y kit antitumoral.
MX388409B (es) Composiciones y metodos para tratar canceres.